Biotech and Pharma Industry News | BioPharma Dive
BioPharma Dive provides news and analysis for biotech and biopharmaceutical executives. We cover topics like clinical trials, drug discovery and development, pharma marketing, FDA …
The biopharma industry outlook on 2024: Guarded optimism for a …
Published Jan. 16, 2024. Ned Pagliarulo Lead Editor. Brian Tucker / BioPharma Dive. Guarded optimism seems to be the mood of the biopharmaceutical industry to start 2024. Last year …
The golden era of GLP-1 drugs: Where we are and what comes next
Sep 23, 2024 · Glucagon-like peptide 1 (GLP-1) receptor agonists (RAs) are entero-pancreatic hormone-based treatments first approved in 2005 for type 2 diabetes (T2D). They are now …
Meso Scale Discovery (MSD): An immunoassay platform with …
Feb 22, 2022 · ADVANTAGES. Sensitivity, Range and Ease-of-Use: In comparison to a conventional ELISA, MSD has higher sensitivity (LLOD 0.1-1.4 pg/mL) and a larger dynamic …
Two decades and $200 billion: AbbVie’s Humira monopoly nears …
Mar 17, 2022 · All told, AbbVie filed about 250 patent applications for Humira in the U.S., 90% of them following the drug's 2002 approval, according to the advocacy group Initiative for …
10 clinical trials to watch in the first half of 2024
Jan 2, 2024 · Moderna and Pfizer both reported promising results in early testing last fall and have moved on to late-stage studies. Moderna appears positioned to get to the finish line first. …
Radiopharmaceuticals for cancer: Making radiation precise
Aug 15, 2023 · When the Food and Drug Administration approved a new prostate cancer drug last year, it validated a bet made by Novartis to acquire the drug’s maker, Endocyte. The decision …
Novartis wins FDA approval for new heart drug, but faces uphill …
Dec 22, 2021 · Novartis priced Leqvio at $3,250 per dose for U.S. sale, meaning the first year of treatment will cost $9,750 and subsequent years $6,500. That’s slightly higher than the $5,400 …
Biotech News - BioPharma Dive
5 days ago · A new biotech, built around protein design, springs from David Baker’s lab. Archon Biosciences, co-founded by the winner of the 2024 Nobel Prize in Chemistry, emerged from …
Takeda targets ‘efficiency’ in restructuring, pipeline cuts
May 9, 2024 · Takeda estimates it will incur about $900 million in restructuring costs during the coming fiscal year, which runs from April to March. The company aims to to improve its core …